Liposomal prostaglandin E1 improves the prognosis of 76 patients with acute ischemic stroke

方堃,朱骏,乔健,董强,韩翔

2011-01-01

Abstract:Objective: To evaluate the efficacy and safety of liposomal prostaglandin E 1 (Lipo-PGE 1) for the treatment of ischemic stroke. Methods: The patients with ischemic stroke within 7 days were randomized into 2 groups. They were treated with Lipo-PGE 1 daily or with Dextran 40 and Danshen injection daily (control). The primary end point was disability at 21 days, dichotomized as a favorable outcome (a score of 100 or 95 on the Barthel Index) or an unfavorable outcome (a score of 0 to 90 on the Barthel Index). The secondary end point was the improvement of the European Stroke Scale. Safety end points included platelet aggregation, clotting time, fibrinogen, D-Dimer, lipid and other adverse events. Results: We enrolled a total of 78 patients in the study and randomly assigned 38 to Lipo-PGE 1 group and 38 to control group. More patients had a favorable outcome in Lipo-PGE 1 group than in control group (26.3% vs 2.6%; P=0.007). In the analysis of the European Stroke Scale, the outcome was also improved after Lipo-PGE 1 as compared that after control treatment (47.37% vs 21.05%; P=0.016). The platelet aggregation was suppressed when the patients was treated with Lipo-PGE 1. The adverse events did not differ significantly between Lipo-PGE 1 group and control group (7.89% and 5.26%; P=0.671). There was no significant difference in the rate of other safety end points. Conclusion: Lipo-PGE 1 can significantly improve clinical outcomes in our patients with acute ischemic stroke; it is safe in the patients.